It’s a summery Monday in Gstaad, and Dr. Barbara Sturm has just finished an afternoon of tennis with her younger daughter, Pepper, who recently turned 11. But if the renowned skincare guru is at all worn out from the sun—or from trying to…
Blog
-
Update Microsoft Windows Now — New 2 Week Security Deadline Confirmed
Update Windows 10 and 11 security now, CISA demands.
NurPhoto via Getty Images
Updated October 18 with expert comment regarding CVE-2025-24990, which is now confirmed as residing in “legacy code installed by default on all Microsoft Windows…
Continue Reading
-
Scientists Discover Rogue Star-Eating Black Hole Far From Home
Welcome back to the Abstract! Here are the studies this week that mounted a defense, felt out of place, found new life, and resurrected the gods of yore.
First, a tale of pregnant stinkbugs, parasitic wasps, and fungi weapons that…
Continue Reading
-
Epomaker Unveils Magcore65 Lite: A Compact, Stable, and Durable Inductive Keyboard
Featuring a 65% layout and a high-strength ABS plastic case, the Epomaker Magcore65 Lite is a keyboard designed for those who prioritize stability and durability, offering a hardcore performance experience.
…
Continue Reading
-
Astronomers detect first ‘heartbeat’ of a newborn star hidden within a powerful cosmic explosion
Gamma ray bursts are the most luminous explosions in the universe, briefly outshining entire galaxies in a violent flash of high energy radiation. These – excuse the pun – astronomical detonations release more energy in a few seconds than our
Continue Reading
-
Astronomers capture first image of a star that exploded twice
A star died in a way that astronomers had long suspected but never seen so clearly. Its remains show two separate layers of debris, the calling card of a double explosion.
The object sits in the Large Magellanic Cloud, a nearby dwarf galaxy about…
Continue Reading
-
‘No one makes money from them’: with MTV channels switching off, is the music video under threat? | Music
The launch of MTV, in 1981, ushered in a new era of music. Showing music videos 24 hours a day, the television channel redefined artist marketing and launched the careers of artists such as Michael Jackson and Madonna, whose public personas…
Continue Reading
-
Pakistan Cricket Board to finalise new ODI skipper ahead of South Africa series – Dawn
- Pakistan Cricket Board to finalise new ODI skipper ahead of South Africa series Dawn
- PCB responds to reports of Shaheen Afridi replacing Rizwan as ODI captain A Sports
- Pakistan captain ‘yet to be finalised for ODI series against South Africa
Continue Reading
-
Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT
Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48.
Google Scholar
Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378–85.
Google Scholar
Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892–9.
Google Scholar
Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. J Hematol Oncol. 2020;13:87.
Google Scholar
Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji RM, Griskevicius L, et al. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis after allogeneic stem cell transplantation. Bone Marrow Transpl. 2024;59:1012–21.
Google Scholar
Penack O, Abouqateb M, Peczynski C, Boreland W, Gülbas Z, Gedde-Dahl T, et al. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer J. 2024;14:45.
Google Scholar
Penack O, Abouqateb M, Peczynski C, Boreland W, Kröger N, Stelljes M, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? Leukemia. 2024;38:1156–63
Ngo D, Samuels D, Chen J, Koller PB, Al Malki MM. A clinical review of the different strategies to minimize hemorrhagic cystitis associated with the use of post-transplantation cyclophosphamide in an allogeneic transplant. Transplant Cell Ther. 2022;28:349–54.
Google Scholar
Duléry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC Cardio Oncol. 2021;3:250–9.
Google Scholar
Rambaldi B, Kim HT, Reynolds C, Chamling Rai S, Arihara Y, et al. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021;5:352–5364.
Google Scholar
Irene GC, Albert E, Anna BV, Rahinatu A, Silvana N, Silvana S, et al. Patterns of infection and infection-related mortality in patients receiving post-transplant high-dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching. Bone Marrow Transpl. 2021;56:818–27.
Google Scholar
Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016;173:444–55.
Google Scholar
Salas MQ, Eikema DJ, Koster L, Maertens J, Passweg J, Finke J, et al. Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transpl. 2024;59:479–88.
Google Scholar
Battipaglia G, Labopin M, Hamladji RM, Blaise D, Chevallier P, Brissot E, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: a retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021;127:209–18
Modi D, Kondrat K, Kim S, Deol A, Ayash L, Ratanatharathorn V, et al. Post-transplant cyclophosphamide versus thymoglobulin in HLA-mismatched unrelated donor transplant for acute myelogenous leukemia and myelodysplastic syndrome. Transplant Cell Ther. 2021;27:760–7.
Google Scholar
Nagler A, Ngoya M, Galimard JE, Labopin M, Blau IW, Kröger N, et al. Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2024;99:1732–45.
Google Scholar
Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a Report on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27:642–9.
Google Scholar
Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transpl. 2013;48:537–43.
Google Scholar
Chen J, Pang A, Zhao Y, Liu L, Ma R, Wei J, et al. Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment, and outcomes. Hematology. 2022;27:293–9.
Google Scholar
Park JH, Lee JH, Lee JH, Park HS, Choi EJ, Kang YA, et al. Incidence, management, and prognosis of graft failure and autologous reconstitution after allogeneic hematopoietic stem cell transplantation. J Korean Med Sci. 2021;36:e151.
Google Scholar
Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood. 2000;96:4096–102.
Google Scholar
Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565–77.
Google Scholar
Chakrabarty JH, Glover J, Schmidt S, Phan M, Bycko M, Duong Q, et al. Incidence and risk factors for graft failure in the modern era of cord blood transplantation. Vox Sang. 2022;117:1405–10.
Google Scholar
Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl. 2018;53:521–34.
Google Scholar
Guru Murthy GS, Logan BR, Bo-Subait S, Beitinjaneh A, Devine S, Farhadfar N, et al. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. Am J Hematol. 2023;98:608–19.
Google Scholar
Cluzeau T, Lambert J, Raus N, Dessaux K, Absi L, Delbos F, et al. Risk factors and outcome of graft failure after HLA-matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI. Bone Marrow Transpl. 2016;51:687–91.
Google Scholar
Ferrà C, Sanz J, Díaz-Pérez MA, Morgades M, Gayoso J, Cabrera JR, et al. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leuk Lymphoma. 2015;56:656–62.
Google Scholar
Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–93.
Google Scholar
Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology. 1996;195:129–39.
Google Scholar
Aversa F, Lustig EB, Geva NO, Prezioso L, Bonomini S, Manfra I, et al. Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide. Blood Adv. 2017;1:2166–75.
Google Scholar
Hoff FW, Chung SS, Patel PA, Permnath N, Khatib J, Ovcina MT, et al. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies: a single-center experience. Transpl Immunol. 2023;77:101808.
Google Scholar
Marco- Ayala J, Sanz JM, Seguí IG, Balaguer-Rosello A, Montoro J, Guerreiro M, et al. Impact of post-transplantation cyclophosphamide on transfusion requirements in HLA-matched sibling peripheral blood stem cell transplantation. Transplant Cell Ther. 2023;29:313.e1–313.e.
Google Scholar
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.
Google Scholar
Ruggeri A, Labopin M, Angelucci E, Blaise D, Ciceri F, Koc Y, et al. Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. Bone Marrow Transpl. 2021;56:1842–9.
Google Scholar
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.
Google Scholar
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.
Google Scholar
Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints, and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2–4.
Google Scholar
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2020.https://www.R-project.org/
Nagler A, Labopin M, Swoboda R, Kulagin A, Velardi A, Sanz J, et al. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2023;58:1008–16.
Google Scholar
Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transpl. 2010;16:1099–106.
Google Scholar
Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573–584.
Google Scholar
Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji RM, et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. J Intern Med. 2019;285:407–18.
Google Scholar
Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020;4:6283–90.
Google Scholar
Schmälter AK, Ngoya M, Galimard JE, Bazarbachi A, Finke J, Kröger N, et al. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients. Blood Cancer J. 2024;14:76.
Google Scholar
Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T-cell dysfunction and suppression. J Clin Invest. 2019;129:2357–73.
Google Scholar
Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to post-transplantation cyclophosphamide. Sci Transl Med. 2013;5:211ra157.
Google Scholar
McCurdy SR, Radojcic V, Tsai HL, Vulic A, Thompson E, Ivcevic S, et al. Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood. 2022;139:608–23.
Google Scholar
Zhao C, Bartock M, Jia B, Shah N, Claxton DF, Wirk B, et al. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant. J Hematol Oncol. 2022;15:64.
Google Scholar
Sawyer J, Elliott T, Orton L, Sowell H, Gatwood K, Shultes K. Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation. Clin Hematol Int. 2024;6:1–10.
Google Scholar
Hickey CL, Zhang MJ, Allbee-Johnson M, Romee R, Majhail NS, Malki MMA, et al. Donor type does not impact late graft failure following reduced-intensity allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis. Transplant Cell Ther. 2025;31:174.e1–12.
Google Scholar
Giammarco S, Raiola AM, Di Grazia C, Bregante S, Gualandi F, Varaldo R, et al. Second haploidentical stem cell transplantation for primary graft failure. Bone Marrow Transpl. 2021;56:1291–6.
Google Scholar
Harada K, Fuji S, Seo S, Kanda J, Ueki T, Kimura F, et al. Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2020;55:1784–95.
Google Scholar
Mata JR, Zahurak M, Rosen N, DeZern AE, Jones RJ, Ambinder AJ. Graft failure incidence, risk factors, and outcomes in patients undergoing non-myeloablative allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide. Transplant Cell Ther. 2024;30:588–96.
Google Scholar
Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273–82.
Google Scholar
Continue Reading